NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), a late-stage clinical biopharmaceutical company focused on developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated LDL-C, has announced the approval of inducement share options. The Compensation Committee of NewAmsterdam's Board of Directors granted options covering 100,000 ordinary shares to one non-executive new hire.
The share options, granted under the 2024 Inducement Plan, have an exercise price of $17.29 per share, equal to the closing market price on October 1, 2024. The shares will vest over four years, with 25% vesting on the one-year anniversary and the remainder vesting in 36 equal monthly installments, subject to continued service. This grant is in accordance with Nasdaq Listing Rule 5635(c)(4).
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), un'azienda biofarmaceutica clinica in fase avanzata che si concentra sullo sviluppo di farmaci orali non statinici per pazienti a rischio di malattie cardiovascolari con LDL-C elevato, ha annunciato l'approvazione delle opzioni di azionariato per incentivare. Il Comitato Compensi del CdA di NewAmsterdam ha concesso opzioni per 100.000 azioni ordinarie a un nuovo assunto non esecutivo.
Le opzioni sulle azioni, concesse nell'ambito del 2024 Inducement Plan, hanno un prezzo di esercizio di $17,29 per azione, pari al prezzo di chiusura del mercato del 1° ottobre 2024. Le azioni matureranno nel corso di quattro anni, con il 25% che matura al primo anniversario e il resto in 36 uguali rate mensili, soggetto a continuato servizio. Questa concessione è in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), una empresa biofarmacéutica clínica en etapa avanzada enfocada en desarrollar medicamentos orales no estatínicos para pacientes en riesgo de enfermedades cardiovasculares con LDL-C elevado, ha anunciado la aprobación de opciones de acciones como incentivo. El Comité de Compensación de la Junta Directiva de NewAmsterdam otorgó opciones que cubren 100,000 acciones ordinarias a un nuevo empleado no ejecutivo.
Las opciones de acciones, otorgadas bajo el 2024 Inducement Plan, tienen un precio de ejercicio de $17.29 por acción, igual al precio de cierre del mercado del 1 de octubre de 2024. Las acciones se consolidarán durante cuatro años, con el 25% consolidándose en el primer aniversario y el resto en 36 pagos mensuales iguales, sujeto a la continuidad del servicio. Esta concesión cumple con la Regla de Cotización Nasdaq 5635(c)(4).
뉴암스테르담 제약 회사 N.V. (Nasdaq: NAMS)는 심혈관 질환 위험이 있는 환자를 위한 구강 비스타틴 약물을 개발하는 후속 단계 임상 생물 제약 회사로서 유도 주식 옵션의 승인을 발표했습니다. 뉴암스테르담 이사의 보상 위원회는 한 비상임 신입 직원에게 100,000주 보통주를 포함하는 옵션을 부여했습니다.
이 주식 옵션은 2024 유도 계획에 따라 부여되었으며, 행사 가격은 $17.29 per share로, 2024년 10월 1일 시장 종가와 동일합니다. 주식은 4년 동안 분할 상환되며, 첫 해의 기념일에 25%가 분할되고, 나머지는 36개월에 걸쳐 동등한 월 할부로 분할됩니다. 이 부여는 Nasdaq 상장 규칙 5635(c)(4)에 따라 이루어진 것입니다.
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), une entreprise biopharmaceutique en phase avancée se concentrant sur le développement de médicaments oraux non statiniques pour les patients à risque de maladies cardiovasculaires avec un LDL-C élevé, a annoncé l'approbation d'options d'actions de précaution. Le Comité de Rémunération du Conseil d'Administration de NewAmsterdam a accordé des options couvrant 100 000 actions ordinaires à un nouvel employé non exécutif.
Les options d'actions, accordées dans le cadre du 2024 Inducement Plan, ont un prix d'exercice de 17,29 $ par action, équivalent au prix de clôture du marché du 1er octobre 2024. Les actions deviendront acquises au cours de quatre ans, avec 25 % devenant acquis à la première date d'anniversaire et le reste en 36 versements mensuels égaux, sous réserve d'une continuité de service. Cette attribution est conforme à la règle de cotation Nasdaq 5635(c)(4).
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), ein biopharmazeutisches Unternehmen in der späten klinischen Phase, das sich auf die Entwicklung von oralen, nicht-statinischen Medikamenten für Patienten mit erhöhtem LDL-C-Risiko für Herz-Kreislauf-Erkrankungen konzentriert, hat die Genehmigung von Anreizaktienoptionen bekannt gegeben. Der Vergütungsausschuss des Vorstands von NewAmsterdam hat Optionen für 100.000 Stammaktien an einen neuen nicht-executive Mitarbeiter vergeben.
Die Aktienoptionen, die im Rahmen des 2024 Inducement Plan gewährt wurden, haben einen Ausübungspreis von $17,29 pro Aktie, gleich dem Schlusskurs vom 1. Oktober 2024. Die Aktien werden über vier Jahre abgewickelt, wobei 25 % am ersten Jahrestag und der Rest in 36 gleichen monatlichen Raten fällig werden, vorbehaltlich einer kontinuierlichen Dienstzeit. Diese Zuteilung erfolgt gemäß der Nasdaq-Listing-Regel 5635(c)(4).
- Attraction of new talent with stock options as incentive
- Alignment of employee interests with company performance through equity compensation
- Potential dilution of existing shareholders' equity
NAARDEN, the Netherlands and MIAMI, Oct. 04, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 100,000 of NewAmsterdam’s ordinary shares to one non-executive new hire. The share options were granted as an inducement material to the employee’s acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).
The share options have an exercise price per share equal to
About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.
Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com
FAQ
What is the exercise price of the inducement share options granted by NewAmsterdam Pharma (NAMS)?
How many ordinary shares are covered by the inducement share options granted by NewAmsterdam Pharma (NAMS)?
What is the vesting schedule for the inducement share options granted by NewAmsterdam Pharma (NAMS)?
Under which plan were the inducement share options granted by NewAmsterdam Pharma (NAMS)?
